Researchers from the University of Michigan and MD Anderson Cancer Center have developed a manganese-based nanoparticle therapy to target tumors [1].
This development could make cancer immunotherapy safer by stimulating anti-tumor immunity without triggering the harmful systemic inflammation often associated with similar treatments [1].
The therapy, named CRYSTAL, stands for Crystal-like STING-Activating nanoassemblies [1]. It is designed to activate the cGAS-STING pathway, a critical component of the innate immune system that helps the body recognize and attack malignant cells [1, 2].
Traditional methods of activating this pathway can lead to widespread inflammation throughout the body, which often limits the effectiveness or safety of the treatment [2]. The CRYSTAL nanoassemblies are engineered to deliver manganese specifically to the tumor site. By localizing the activation, the therapy aims to maximize the immune response against the cancer, while protecting healthy tissues [1, 2].
The project was a collaborative effort between the University of Michigan College of Pharmacy in Ann Arbor and the University of Texas MD Anderson Cancer Center in Houston [1]. The research team said the findings in May 2026 [1].
By utilizing these nanoparticles, the team believes they can create a more precise delivery system for immunotherapy. This approach allows the immune system to identify tumors more effectively without the risks associated with a systemic inflammatory storm [2].
“The CRYSTAL therapy targets tumors by activating the immune system while avoiding systemic inflammation.”
The development of CRYSTAL represents a shift toward localized immunotherapy. By isolating the activation of the cGAS-STING pathway to the tumor environment, researchers are attempting to bypass the 'cytokine storm' or systemic inflammation that has historically hindered the use of STING agonists in human clinical trials.
